Greetings and welcome to the CVRx Third Quarter 2023 Earnings Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mike Vallie from ICR Westwicke. Good afternoon. Thank you for joining us today for CVRx's third quarter 2023 earnings conference call. Joining me on today's call are the company's President and Chief Executive Officer, Nadim Yared; and its Chief Financial Officer, Jared Oasheim. The remarks today will contain forward-looking statements, including statements about financial guidance. The statements are based on plans and expectations as of today, which may change over time. In addition, actual results could differ materially due to a number of risks and uncertainties, including those identified in the earnings release issued prior to this call and in the company's SEC filings, including the upcoming Form 10-Q that will be filed with the SEC. I would now like to turn the call over to CVRx's President and Chief Executive Officer, Nadim Yared.

Thank you, Mike, and thanks to everyone for joining us. I'll begin today's call by providing an overview of our third quarter performance, followed by an operational update and a review of our financial results by our CFO, Jared Oasheim. Then I will conclude with our thoughts for the rest of the year, before turning to Q&A. We maintain positive momentum in the third quarter, building on the strengths we delivered during the first half of 2023. In particular, the performance within our U.S. heart failure business continued to surpass our expectations by growing by more than 90% in the quarter. This is a testament to our team's ability to accelerate the adoption of Barostim through the increased scale of our commercial organization and our marketing and awareness efforts. Barostim therapy continues to gain traction, and the feedback we receive from physicians and patients is very positive. Now, let's dive into the details of our performance. Starting with the review of the quarter, worldwide revenue was $10.5 million, a 70% increase over the third quarter of 2022. This was a direct result of execution within our U.S. heart failure business, which grew by 92% over the prior year. These results were achieved through the increased utilization of Barostim among our existing customer base. The continued addition of new active implanting centers, the measured expansion of new sales territories in the U.S. and increased awareness among physicians and patients. As a result of our sustained top line revenue growth stemming from our focused investments in higher return on investment initiatives, in combination with the prudent management of our operating spend, we have seen a continued reduction in our cash burn rate. It is highly encouraging to see operating leverage within our business. And we anticipate this trend to be sustainable as we move into 2024 and beyond. Turning to an update on our operational progress during the third quarter. As a reminder, our focus areas are the continued expansion of our commercial infrastructure in the expansion of our clinical body of evidence. Starting with the expansion of our commercial infrastructure, we've expanded our commercial reach, adding three new U.S. sales territories as anticipated, bringing our total to 35. During the quarter, we also made progress with our marketing efforts, which included our direct-to-consumer and patient education programs. As we move forward, we will continue working to fine-tune these initiatives to drive increased awareness of patients and healthcare providers. Moving to our second focus area, the expansion of our clinical body of evidence and in particular, on the regulatory front. Our ongoing interaction with the FDA regarding our potential label expansion following the post-market BeAT-HF data continues to progress as expected. The FDA has provided us with their initial feedback, and we have responded to their questions. We continue to anticipate a potential decision by year-end. Now for an update on CMS and the proposed Outpatient Prospective Payment System, or OPPS for 2024. Earlier this year, we submitted the request to CMS to be assigned a new technology APC payment code as our transitional pass-through payment expires at the end of 2023. In August, the company presented before a CMS Advisory Panel and received a 5-0 vote in favor of mapping to the higher paying code, APC1580, which reimburses approximately $45,000. While this is encouraging, it is important to note that this vote is non-binding. If CMS instead decides to map Barostim to APC5465 without the transitional pass-through payment for 2024, which is the basis for the company's plans, then the average reimbursement to hospitals will be approximately $30,000. The final outpatient payment rule is expected to be published in late November. We are pleased with the accomplishments of the third quarter and the overall progress throughout 2023. Our performance has been consistently strong, largely driven by exceptional growth in our U.S. heart failure business. We have steadily expanded our commercial reach and made strides in marketing and patient education. Our ongoing discussions with the FDA and a positive vote from the CMS Advisory Panel in August are encouraging, though our guidance does not hinge on these outcomes. We remain confident in our business to help bring relief to many patients suffering from heart failure. I'll now turn the call over to Jared to review our financials.

Thanks, Nadim. In the third quarter, total revenue generated was $10.5 million, representing an increase of $4.3 million or 70% compared to the same period last year. Revenue generated in the U.S. was $9.6 million in the current quarter, reflecting growth of 90% over the same period last year. Heart failure revenue in the U.S. totaled $9.4 million in the current quarter on a total of 303 revenue units compared to $4.9 million in the third quarter of last year on 167 revenue units. The increases were primarily driven by continued growth in the U.S. heart failure business, as a result of the expansion into new sales territories, new accounts and increased physician and patient awareness of Barostim. At the end of the current quarter, we had a total of 159 active implanting centers, compared to 91 on September 30, 2022, and 140 on June 30, 2023. We also had 35 sales territories in the U.S. at the end of the current quarter, compared to 23 on September 30, 2022, and 32 on June 30, 2023. Revenue generated in Europe was $0.9 million in the current quarter, representing a decrease of 19% compared to the same period last year. Total revenue units in Europe decreased from 61 in Q3 of 2022 to 47 in the current quarter. The number of sales territories in Europe remained consistent at six for the three months ended September 30, 2023. Gross profit for the three months ended September 30, 2023, was $8.8 million, an increase of $4 million compared to the three months ended September 30, 2022. Gross margin for the current quarter increased to 84%, compared to 78% for the same period last year. This increase was due primarily to a decrease in the cost per unit, driven by an increase in the production volume. Research and development expenses for the current quarter were $2.7 million, reflecting an increase of 18% compared to the same period last year. This change was driven by a $0.3 million increase in compensation expenses as a result of increased headcount and a $0.1 million increase in non-cash stock-based compensation expense. SG&A expenses for the current quarter were $15.7 million, representing an increase of 23% compared to the same period last year. This change was primarily driven by a $1.9 million increase in compensation expenses, mainly as a result of increased headcount, a $0.5 million increase in non-cash stock-based compensation expense, a $0.3 million increase in marketing and advertising expenses associated with the commercialization of Barostim in the U.S., and a $0.1 million increase in travel expenses. Interest expense increased $0.5 million for the three months ended September 30, 2023, compared to the three months ended September 30, 2022. This increase was driven by the interest expense on borrowings under the loan agreement entered into on October 31, 2022. Other income net was $1.1 million in the current quarter, compared to $0.3 million for the same period last year. The income in the third quarter of 2023 was primarily driven by interest income on our interest-bearing accounts. Net loss for the current quarter was $9 million, or $0.43 per share, compared to a net loss of $9.8 million, or $0.48 per share, for the same period last year. Net loss per share was based on 20.8 million weighted average shares outstanding for the third quarter of 2023 and 20.6 million weighted average shares outstanding for the third quarter of 2022. At the end of the third quarter, cash and cash equivalents were $83 million. Net cash used in operating and investing activities was $8.2 million for the third quarter. This is compared to net cash used in operating and investing activities of $13 million for the three months ended June 30, 2023, which included our annual premium for our directors and officers insurance of approximately $2 million. The improvement in our cash burn has been driven by improved gross margins, increased productivity from our U.S. sales team and a reduction in our R&D spend associated with the BeAT-HF trial. Now turning to guidance. For the full year of 2023, we now expect total revenue between $38.5 million and $39 million, up from $37 million to $38.5 million. We continue to expect full year gross margin between 83% and 84%. And we now expect operating expenses between $77 million and $78 million, down from $78 million to $80 million. For the fourth quarter of 2023, we expect to report total revenue between $10.5 million and $11 million. I would now like to turn the call back over to Nadim.

Thanks, Jared. Our approach to advancing the adoption of Barostim, while upholding our financial stability, has yielded positive outcomes once again, reflecting the effectiveness of our operational model. Our operations are performing well with steady revenue growth, improved margins, and a reduction in our cash burn. Our solid performance in the third quarter has led us to make another upward adjustment to our revenue projection for the year. We're looking forward to carrying this momentum into this final quarter of 2023 and beyond. And now I would like to open the line for questions.

Thank you. And our first question comes from Robbie Marcus with JPMorgan. Please proceed.

Hi, this is Alan on for Robbie. Congrats on a good quarter. I just had one quick question to start on your forward-looking guidance. You've been able to pretty consistently guide and beat the guide, several quarters in a row now. And when I look at your implied guidance for fourth quarter, given the really strong implanting center adds, you had in the third quarter. It looks like the benchmark should - it looks like kind of a very achievable floor once again. So what kind of dynamics are you seeing so far in October that lead you to believe that this is the right guide for fourth quarter?

Hi, Alan, this is Jared. I'll take that one. Thanks for joining the call here. So yes, we've continued to exceed expectations on our quarterly growth throughout 2023. That includes the number of active implanting centers, but then also being able to exceed the top end of the guidance that we've given over the last few quarters. So, we've been pretty happy with the growth that we've seen throughout 2023. I'd say the one thing to consider here for Q3 results as we march into Q4, was what we saw in Europe. Europe has continued to be flat, roughly around that $1 million mark on a quarterly basis. But again, most of our focus is on the U.S. business, and we're seeing really, really good results on that side of it. One thing to call out. Nadim mentioned it earlier was around the OPPS final ruling coming out in November. And we did mention that there is the non-binding vote that went our direction, so it was 5-0 in our favor. And our base case is assuming that we don't get mapped to the new attach APC, that would increase the reimbursement for our hospitals. But if we are surprised and we do get mapped to that new payment code, there is a chance that some of our customers that may have had complicated add-on payment calculations in the past could delay procedures from December into January. So that they could potentially benefit from that more predictable payment code, APC1580, and that approximate reimbursement of $45,000. So I think taking all of that into consideration, we've seen good results in the U.S., kind of steady results in Europe and then the unknown related to that payment code coming out in November. Just kind of all came together for the guidance that we put out for the fourth quarter. But again, we were really happy to be able to push that full year guidance number up.

And then just a quick follow-up. I know the base case right now is that you don't get mapped to 1580 that you stay on 5465. But if you do get mapped to 1580, will you essentially be able to hold ASPs kind of where they are in off the $30,000-plus range? Thank you.

Yes, it's a good question. So, I think we've seen ASPs north of that $30,000 throughout 2023. We've been really happy with the results so far this year based on that add-on payment that we have had. I think as we march into 2024, without going into detailed guidance there. I think it'd be hard to say that you could maintain those ASPs at that level longer term, but you could be approaching those numbers, right? So maybe not exactly the $30,000 or $31,000, but maybe high 20s would definitely be conceivable.

Our next question comes from the line of Matthew O'Brien with Piper Sandler. Please proceed.

Thanks for taking the questions. Just to maybe follow-up a little bit on the last question about the unanimous vote. I know Nadim and Jared, you're data driven, but there's no guarantees I get all that. But I'm sure you've looked at this. How often will CMS look at something that has a unanimous vote and then say, no, we're going to do something different? And then how often will they look at something like that and say, yes, it makes sense. We're going to go with this recommendation. Any kind of framework you can provide on that?

Good evening, Matt. And by the way, thank you for joining us. I know it's been a busy week for you with DCT and everything going on. Listen, no. Actually, we have not looked at statistics of the past in here to be exact. I don't have a percentage. But the vote is non-binding. This is a pattern very similar to the FDA panel. The FDA can follow the recommendation and they can just ignore it. We do not have any indications to believe it's going to go one way or the other, except to note that the chances of getting it has increased. That's all I can say right now, Matt.

Okay. That makes total sense. And then the follow-up is just on the label expansion. Just talk maybe a little bit about where you're at with that process, and then maybe when we can get an update there? Thank you.

Yes. So under the MDUFA, the Medical Device User Fee Agreement number 5, which is the current agreement that is in place between FDA and the industry. FDA has 180 days to respond in 95% of the PMA supplement. So, we hope that we are among those 95%, is where FDA will meet the 180 days clock. When we do the count of all of the stoppage days that happened during this interactive session between when FDA gives us feedback and we respond to the feedback, when we add all of those stoppage, we still have time to get to the 180 days in this year, before the end of December. But again, it's no guarantee that we fit within the 95% committed numbers of PMA supplement that FDA commits to do within 180 days.

Understood. Thanks so much.

Thank you, Matt.

The next question comes from the line of Margaret Kaczor Andrew with William Blair. Please proceed.

Hi, good afternoon guys. Thanks for taking the questions. I wanted to maybe start on utilization. I know you guys have been pretty vocal about new center utilization. Maybe doing one or two patients upfront and then waiting for a few months, and maybe progressing until they get to 24 months plus. But you've added quite a few of these centers. Maybe there's a bigger cohort within that six to 12 months. Any trends that you guys can walk us through? Or is it a pretty large scatter plot within that group?

Hi, Margaret, thanks for the question. Yes, I think the trends have continued to be what we've seen in the past, where we saw a lot of those centers coming on board, treating a handful of patients, and then waiting for the results both for the reimbursement because of the complexity of the add-on payment, that TPT, but then also wanting to see the impact on their patients themselves. No matter how much clinical data there is, they still want to see how it works in their patients. And then after about six, seven months of waiting to see what those answers are, then they start treating more and more patients over time. And the trend has continued, where the longer an account is active, the more patients they're treating on average. And so, we've seen that trend continue here into the third quarter.

Okay. That's helpful. And then you also referenced previously in quarters that you did see kind of this high level of interest at your booth following some of the data presentations earlier this year. Has that continued? Has there been follow-through, and not only follow-through of continued interest, but maybe making their way through the hospital processes to get Barostim on board?

Hi Margaret, yes, thank you for the question. Actually, we had recently another scientific meeting, the Heart Failure Society of America, where in my opinion and the opinion of our team, this has been by far the best scientific meeting that CVRx has even been participant to. We were the darling here of that congress. And there was another couple of opportunities during that scientific session to have the CVRx data presented again to heart failure specialists. So that is increasing, the exposure of this data through those scientific meetings to centers. Questions so far, I can't comment on it specifically one-by-one, but we have not seen any negative impact. And all I can point out, is to the results here, the addition of centers to say that, if there was an impact so far, it has been positive net-net.

Okay. Fantastic. Thank you, guys. Appreciate it.

Thank you.

And our next question comes from the line of Alex Nowak with Craig-Hallum. Please proceed.

Okay. Great. Good afternoon, everyone. Congrats on the really nice results here. I want to ask on GLP-1. It's obviously all the talk out right now in med tech. There's been some talk about what it can do around heart failure symptoms with these patients. There's some studies that are ongoing right now, about assessing it in the preserved ejection heart failure side of it. How do you think about GLP-1s changing the potential patient pool for Barostim longer term?

Yes, Alex, again, thank you for joining. I know it's a busy week for you, too. Listen, regarding GLP-1, we're excited about the positive impact of that therapy on obesity and type 2 diabetes. Clearly, patients needed some solution. And this is, from our perspective, a welcome solution to many patients. However, one of the early results from that drug in heart failure was to note that the heart rate unfortunately increases with this drug. And we all know that in heart failure with reduced ejection fraction, an increased heart rate is considered a safety concern. So, we've seen some publications, particularly in more recent one by Dr. Murray, among others and Dr. Butler highlighting this fact and raising the question whether this drug can be studied safely in the HFrEF patient population. The other thing I would like to note is that paradoxically, when a patient has heart failure with reduced ejection fraction, heavier weight is not necessarily a negative outcome compared to lesser weight, i.e., patients who have more or larger weight actually have better outcomes in HFrEF than patients who are super lightweight or super thin. It's a paradox. This is one of those disease areas where a weight-reducing drug might not necessarily be beneficial. Now - but all that said, we don't know until they are on clinical trials. So we will keep a watchful eye on all of these developments. But no matter what, we do not expect any material impact on our business.

Okay. It makes total sense. And I might have missed this in the prepared remarks. The pullback in OpEx spend, even amid the new rep hires, the R&D side makes sense. But G&A, sales and marketing, why are some of the cost reductions there? What happened? And is that pretty sustainable? Is this a good cost basis to continue for 2024 on your path to cash flow breakeven?

Yes. Alex, I'll take that one. Yes, I wouldn't call it necessarily a pullback in our spend but more pointing towards seasonality in the second quarter. We often see some additional spend related to trade shows in our sales and marketing line. So, seeing us move into the third quarter with more revenue and a little bit less in overall sales and marketing isn't a surprise necessarily. So, I do think that the leverage we're seeing in this model on the sales and marketing side is definitely sustainable as we move forward, continue to grow and see more of that total coming down to the bottom line to help us out and reduce that cash burn number. On the R&D side of the house, this is planned. Right? So, we expected BeAT-HF spend to start slowing down after we left the second quarter. So seeing that reduction in research and development was in line with expectations for us.

Excellent. Appreciate the update. Thank you.

And our final question comes from the line of Frank Takkinen with Lake Street Capital Markets. Please proceed.

Hi, great. Thanks for taking the questions. Wanted to start with one related to the initial FDA feedback you spoke to, Nadim. I'm assuming you can't go into great detail, but my assumption being you've remained in the 180-day window within 2023. Is it fair to assume that some of the interaction is less impactful, or we can say maybe non-crucial to the approvability, or maybe it was more streamlined? Can you comment on that at all or if there were any significant questions that they presented to you?

Hi, Frank, how are you? Super smart question. Yes, I would - you are correct. I prefer not to negotiate with FDA in the public eyes in here. That said, you are correct on one thing. When FDA submits a question, irrespective of the difficulty of the question, the clock is stopped. And then we have to answer the question and provide the data that we feel comfortable that this additional data or additional analysis answers the question of FDA. And here, kudos to our team and the steering committee, with whom we're working to be able to get these questions, analyze the data, write the answer and submit the answers to the FDA in a timely fashion that whereby all of the clock stoppage, when added together, they still allow us to hit the 180 days in this year. But let me be clear on one thing. You cannot infer from that any elements on the severity of the question or the nature of the question, the fact that our team has done a fantastic job responding very quickly.

Got it. Fair enough. Makes sense. And I wanted to theorize a little bit into 2024. Assuming some of these items end up in your favor, understanding you guys are assuming a base case, but assuming some of them are in your favor. Can you maybe talk about if there would be any material commercial changes, whether that's headcount accelerations, direct to consumer, or anything in that category?

Frank, I love the question, but at this point, I think we're going to pass on providing any additional color on 2024. I think we're feeling really positive based on the results we've seen so far in 2023 and pretty hopeful based on the non-binding vote that we got from the advisory panel on what we could possibly see for a payment level for 2024. But at this point, I don't think we're going to commit to any additional ads or additional spend until we actually see the real results come out here from the letter in later November.

Got it. Fair enough. I'll stop there. Thanks for taking the questions.

Thank you.

Ladies and gentlemen, we have reached the end of the question-and-answer session. I'd like to turn the call back to Nadim Yared for closing remarks.

Thank you, operator, and thanks again to everyone for joining us for our third quarter earnings call. We appreciate your ongoing support, and we look forward to updating you on our progress on our next update.

Thank you. This concludes today's conference. You may now disconnect your lines at this time. Have a good day.